Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.

Moghavem, Nuriel; Henderson, Victor W; Greicius, Michael D

Moghavem, Nuriel; Henderson, Victor W; Greicius, Michael D.

Affiliation

Moghavem N; Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Henderson VW; Departments of Epidemiology & Population Health and of Neurology & Neurological Sciences, Stanford University, Stanford, CA.
Greicius MD; Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA.

Ann Neurol ; 90(3): 331-333, 2021 09.

Article in En | MEDLINE | ID: mdl-34278596

Subject(s)

Alzheimer Disease/economics; Antibodies, Monoclonal, Humanized/economics; Insurance Coverage/economics; Medicare/economics; Alzheimer Disease/drug therapy; Alzheimer Disease/epidemiology; Antibodies, Monoclonal, Humanized/therapeutic use; Clinical Trials, Phase III as Topic/methods; Humans; Treatment Outcome; United States/epidemiology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Medicare / Insurance Coverage / Alzheimer Disease / Antibodies, Monoclonal, Humanized Limits: Humans Country/Region as subject: America do norte Language: En Journal: Ann Neurol Year: 2021 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google